Jeffrey M. Leiden

2014 - Vertex Pharmaceuticals

In 2014, Jeffrey M. Leiden earned a total compensation of $36.6M as Chairman, President & CEO at Vertex Pharmaceuticals, a 179% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,970,000
Option Awards$12,669,261
Salary$1,100,000
Stock Awards$19,883,350
Other$12,857
Total$36,635,468

Leiden received $19.9M in stock awards, accounting for 54.27% of the total pay in 2014.

Leiden also received $3M in non-equity incentive plan, $12.7M in option awards, $1.1M in salary and $12.9K in other compensation.

Rankings

In 2014, Jeffrey M. Leiden's compensation ranked 34th out of 12,995 executives tracked by ExecPay. In other words, Leiden earned more than 99.7% of executives.

ClassificationRankingPercentile
All
34
out of 12,995
100th
Division
Manufacturing
9
out of 4,966
100th
Major group
Chemicals And Allied Products
3
out of 1,653
100th
Industry group
Drugs
3
out of 1,327
100th
Industry
Pharmaceutical Preparations
3
out of 1,017
100th
Source: SEC filing on April 28, 2017.

Leiden's colleagues

We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2014.

2014

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2014

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2014

Jeffrey Chodakewitz

Vertex Pharmaceuticals

Chief Medical Officer

2014

Kenneth Horton

Vertex Pharmaceuticals

Chief Legal Officer

News

You may also like